![Perioperative Management of New Anticoagulants: Novel Drugs and Concepts - Anesthesia Patient Safety Foundation Perioperative Management of New Anticoagulants: Novel Drugs and Concepts - Anesthesia Patient Safety Foundation](https://www.apsf.org/wp-content/uploads/newsletters/2017/Oct/images/NOAC_FIG2.png)
Perioperative Management of New Anticoagulants: Novel Drugs and Concepts - Anesthesia Patient Safety Foundation
![Twitter 上的Arie Blitz, MD, MBA:"#Apixaban to Prevent #VTE in Patients With Cancer https://t.co/uC5076Lx6C via @practiceupdate #oncology https://t.co/v3AkMYi6FA" / Twitter Twitter 上的Arie Blitz, MD, MBA:"#Apixaban to Prevent #VTE in Patients With Cancer https://t.co/uC5076Lx6C via @practiceupdate #oncology https://t.co/v3AkMYi6FA" / Twitter](https://pbs.twimg.com/media/D0iAEjZWkAAUadE.jpg)
Twitter 上的Arie Blitz, MD, MBA:"#Apixaban to Prevent #VTE in Patients With Cancer https://t.co/uC5076Lx6C via @practiceupdate #oncology https://t.co/v3AkMYi6FA" / Twitter
![Dentistry Journal | Free Full-Text | New Direct Oral Anticoagulants (DOAC) and Their Use Today | HTML Dentistry Journal | Free Full-Text | New Direct Oral Anticoagulants (DOAC) and Their Use Today | HTML](https://www.mdpi.com/dentistry/dentistry-04-00005/article_deploy/html/images/dentistry-04-00005-g001.png)
Dentistry Journal | Free Full-Text | New Direct Oral Anticoagulants (DOAC) and Their Use Today | HTML
![The Direct Oral Anticoagulants Apixaban, Rivaroxaban, and Edoxaban | American Society for Clinical Laboratory Science The Direct Oral Anticoagulants Apixaban, Rivaroxaban, and Edoxaban | American Society for Clinical Laboratory Science](http://clsjournal.ascls.org/content/ascls/30/1/2/F1.large.jpg)
The Direct Oral Anticoagulants Apixaban, Rivaroxaban, and Edoxaban | American Society for Clinical Laboratory Science
![Reversal of Apixaban and Rivaroxaban Anticoagulation by Andexanet Alfa in ANNEXA-A and ANNEXA-R as Assessed by Non-Tissue Factor-Initiated Thrombin Generation Independent of Tissue Factor Pathway Inhibitor - European Medical Journal Reversal of Apixaban and Rivaroxaban Anticoagulation by Andexanet Alfa in ANNEXA-A and ANNEXA-R as Assessed by Non-Tissue Factor-Initiated Thrombin Generation Independent of Tissue Factor Pathway Inhibitor - European Medical Journal](https://emj.emg-health.com/wp-content/uploads/sites/2/2018/10/Figure-1-Andexanet-alfa-mechanism-of-action-940x563.png)
Reversal of Apixaban and Rivaroxaban Anticoagulation by Andexanet Alfa in ANNEXA-A and ANNEXA-R as Assessed by Non-Tissue Factor-Initiated Thrombin Generation Independent of Tissue Factor Pathway Inhibitor - European Medical Journal
![Mechanism of action of the non-vitamin K antagonist oral anticoagulants... | Download Scientific Diagram Mechanism of action of the non-vitamin K antagonist oral anticoagulants... | Download Scientific Diagram](https://www.researchgate.net/profile/James-Gagg/publication/281235144/figure/fig1/AS:284620739366923@1444870280861/Mechanism-of-action-of-the-non-vitamin-K-antagonist-oral-anticoagulants-NOACs-Anti-Xa_Q320.jpg)
Mechanism of action of the non-vitamin K antagonist oral anticoagulants... | Download Scientific Diagram
![PDF] Pharmacology of new oral anticoagulants: mechanism of action, pharmacokinetics, pharmacodynamics | Semantic Scholar PDF] Pharmacology of new oral anticoagulants: mechanism of action, pharmacokinetics, pharmacodynamics | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/64d620321dfe4fcc85537c0e0a6f9260a019b8fa/2-Figure1-1.png)
PDF] Pharmacology of new oral anticoagulants: mechanism of action, pharmacokinetics, pharmacodynamics | Semantic Scholar
![Rivaroxaban and other novel oral anticoagulants: pharmacokinetics in healthy subjects, specific patient populations and relevance of coagulation monitoring | Thrombosis Journal | Full Text Rivaroxaban and other novel oral anticoagulants: pharmacokinetics in healthy subjects, specific patient populations and relevance of coagulation monitoring | Thrombosis Journal | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2F1477-9560-11-10/MediaObjects/12959_2013_Article_185_Fig1_HTML.jpg)
Rivaroxaban and other novel oral anticoagulants: pharmacokinetics in healthy subjects, specific patient populations and relevance of coagulation monitoring | Thrombosis Journal | Full Text
![Apixaban: An oral anticoagulant having unique mechanism of action with better safety and efficacy profile Fazeel Z A - MAMC J Med Sci Apixaban: An oral anticoagulant having unique mechanism of action with better safety and efficacy profile Fazeel Z A - MAMC J Med Sci](https://www.mamcjms.in/articles/2016/2/2/images/MAMCJMedSci_2016_2_2_63_182723_f1.jpg)
Apixaban: An oral anticoagulant having unique mechanism of action with better safety and efficacy profile Fazeel Z A - MAMC J Med Sci
![rivaroxaban and apixaban for stroke prevention in atrial fibrillation | Leaders in Pharmaceutical Business Intelligence (LPBI) Group rivaroxaban and apixaban for stroke prevention in atrial fibrillation | Leaders in Pharmaceutical Business Intelligence (LPBI) Group](https://i0.wp.com/pharmaceuticalintelligence.com/wp-content/uploads/2014/05/eliquis-2.jpg)
rivaroxaban and apixaban for stroke prevention in atrial fibrillation | Leaders in Pharmaceutical Business Intelligence (LPBI) Group
![Rivaroxaban for the treatment and prevention of thromboembolic disease - Antoniou - 2015 - Journal of Pharmacy and Pharmacology - Wiley Online Library Rivaroxaban for the treatment and prevention of thromboembolic disease - Antoniou - 2015 - Journal of Pharmacy and Pharmacology - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/72a15a22-fb0e-48f4-b7ed-629d1716083c/jphp12387-fig-0001-m.jpg)